Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer patients & supplements

This article was originally published in The Tan Sheet

Executive Summary

Increased alternative medicine education for health care providers serving cancer patients is necessary due to high prevalence of supplement use among cancer patients, Ruth Patterson, PhD, Fred Hutchinson Cancer Center, et al., conclude from data obtained in survey appearing in the September Journal of Alternative & Complementary Medicine. Phone interviews of 356 cancer patients selected from the Washington State Cancer Surveillance System indicated 64.6% take supplements, Patterson et al. find. Users spent an average of $68 on alternative medicine per year and were "more likely to be female, younger and more educated than non-users," researchers note. Study limitations included lack of ethnic diversity among respondents, inability to ensure consistent behavior among respondents and non-respondents...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel